Risk of bias summary.

<p>Richard S in 2020 represents the IMbrave150 clinical trial; Robin K in 2022 represents the COSMIC-312 clinical trial.</p> <p>(TIF)</p>

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Heng Xiang (679982) (author)
مؤلفون آخرون:	Zhihua She (20756365) (author), Liting Wang (717544) (author), Ye Peng (320691) (author), Lei Zhang (38117) (author), Chongqing Tan (387068) (author)
منشور في:	2025
الموضوعات:	Medicine Genetics Pharmacology Biotechnology Evolutionary Biology Science Policy Infectious Diseases Virology Biological Sciences not elsewhere classified probabilistic sensitivity analyses atezolizumab plus aevacizumab atezolizumab plus aabozantinib advanced hepatocellular carcinoma 054 per qaly 000 per qaly included 761 patients included 487 patients probabilistic sensitivity analysis xlink "> findings xlink "> assessing advanced hcc patients assessed via one effectiveness analysis suggested xlink "> compared network treatment comparison 528 life years xlink "> patients regarding effectiveness analysis hcc ). wtp threshold two strategies sensitive factors pay threshold optimal choice november 2020 hazard ratios granted approval either bevacizumab effectiveness ratios effectiveness probabilities becomes imperative adjusted life 365 qalys
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة